CL2013000390A1 - Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer. - Google Patents

Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer.

Info

Publication number: CL2013000390A1
Authority: CL; Chile
Prior art keywords: n3pglu; binds; disease; pharmaceutical composition; monoclonal antibody
Prior art date: 2010-08-12

Application number

CL2013000390A

Other languages

English (en)

Inventor

Jirong Lu

Ying Tang

Ronald Bradley Demattos

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-12

Filing date

2013-02-08

Publication date

2014-03-21

2013-02-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-03-21 Publication of CL2013000390A1 publication Critical patent/CL2013000390A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CL2013000390A 2010-08-12 2013-02-08 Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer. CL2013000390A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37302610P	2010-08-12	2010-08-12

Publications (1)

Publication Number	Publication Date
CL2013000390A1 true CL2013000390A1 (es)	2014-03-21

Family

ID=44543826

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000390A CL2013000390A1 (es)	2010-08-12	2013-02-08	Anticuerpo monoclonal que se une al peptido beta amiloide n3pglu o fragmento de union a antigeno del mismo; composicion farmaceutica que lo comprende; y su uso para tratar la enfermedad de alzheimer.

Country Status (41)

Country	Link
US (2)	US8679498B2 (es)
EP (3)	EP3042917B1 (es)
JP (2)	JP5980207B2 (es)
KR (1)	KR101498833B1 (es)
CN (2)	CN105111308B (es)
AU (1)	AU2011289629B2 (es)
BR (1)	BR112013004056B8 (es)
CA (1)	CA2805114C (es)
CL (1)	CL2013000390A1 (es)
CO (1)	CO6670526A2 (es)
CR (1)	CR20130016A (es)
CY (2)	CY1120144T1 (es)
DK (3)	DK3042917T3 (es)
DO (1)	DOP2013000029A (es)
EA (1)	EA023021B1 (es)
EC (1)	ECSP13012436A (es)
ES (3)	ES2564252T3 (es)
FI (1)	FIC20250038I1 (es)
FR (1)	FR25C1055I1 (es)
GT (1)	GT201300036A (es)
HR (3)	HRP20160151T1 (es)
HU (2)	HUE037524T2 (es)
IL (2)	IL285226B2 (es)
LT (3)	LT3042917T (es)
MA (1)	MA34461B1 (es)
ME (3)	ME02352B (es)
MX (2)	MX342782B (es)
MY (2)	MY181969A (es)
NL (1)	NL301359I2 (es)
NO (2)	NO3042917T3 (es)
NZ (2)	NZ626665A (es)
PE (1)	PE20130817A1 (es)
PH (1)	PH12013500277A1 (es)
PL (3)	PL3042917T3 (es)
PT (2)	PT3339323T (es)
RS (3)	RS59652B1 (es)
SG (2)	SG187586A1 (es)
SI (3)	SI3339323T1 (es)
UA (1)	UA107600C2 (es)
WO (1)	WO2012021469A1 (es)
ZA (1)	ZA201300437B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20140049T1 (hr)	2007-01-05	2014-02-28	University Of Zürich	Anti beta-amiloid antitijela i njihova upotreba
SI3339323T1 (sl) *	2010-08-12	2019-12-31	Eli Lilly And Company	Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
WO2012136552A1 (en)	2011-04-08	2012-10-11	H. Lundbeck A/S	ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
CA2938129A1 (en) *	2014-02-03	2015-08-06	Cangene Corporation	Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en)	2014-05-15	2015-11-19	Biogen Ma Inc.	Methods for the detection of amyloid beta oligomers in biological samples
CA2954476C (en)	2014-07-10	2023-09-19	Novartis Ag	Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh) *	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
US20170363645A1 (en)	2014-12-19	2017-12-21	Probiodrug Ag	Novel Method for the Detection of pGlu-Abeta Peptides
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
MY195059A (en) *	2015-09-23	2023-01-05	Regeneron Pharma	Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
JP6993699B2 (ja)	2016-01-11	2022-02-03	ウニヴェルズィテート・ツューリヒ	ヒトインターロイキン－２に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
JOP20170004B1 (ar) *	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740944A (zh) *	2016-03-15	2017-12-01	美國禮來大藥廠	組合療法
AR107774A1 (es) *	2016-03-16	2018-05-30	Lilly Co Eli	Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) *	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en)	2016-07-04	2018-07-31	H. Lundbeck A/S	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP6949102B2 (ja) *	2016-08-09	2021-10-13	イーライリリーアンドカンパニー	併用療法
WO2018034977A1 (en)	2016-08-18	2018-02-22	Eli Lilly And Company	Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
AR110470A1 (es) *	2016-10-21	2019-04-03	Lilly Co Eli	Terapia de combinación para tratar la enfermedad de alzheimer
LT3532064T (lt)	2016-10-28	2020-09-25	H. Lundbeck A/S	Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru)	2016-10-28	2020-11-30	Х. Лундбекк А/С	Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
TW201827467A (zh) *	2016-11-03	2018-08-01	比利時商健生藥品公司	焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI789644B (zh) *	2017-04-20	2023-01-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
CN111201030B (zh)	2017-07-25	2024-11-01	真和制药有限公司	通过阻断tim-3和其配体的相互作用治疗癌症
MD3672631T3 (ro)	2017-08-22	2023-09-30	Biogen Ma Inc	Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
RU2020118913A (ru)	2017-12-14	2022-01-14	Х. Лундбекк А/С (H. Lundbeck A/S)	Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов
AR113926A1 (es)	2017-12-14	2020-07-01	H Lundbeck As	Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en)	2017-12-20	2022-12-27	H. Lundbeck A/S	Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
BR112020015736A2 (pt) *	2018-02-11	2020-12-08	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo
MA51996A (fr) *	2018-03-13	2021-01-20	Smivet B V	Anticorps à domaine unique se liant à la neurotoxine tétanique
KR20210124308A (ko)	2019-01-30	2021-10-14	트루바인딩 아이엔씨.	항-gal3 항체 및 이의 용도
SG11202110504XA (en) *	2019-03-26	2021-10-28	Janssen Pharmaceutica Nv	ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
EP4045641A1 (en)	2019-10-15	2022-08-24	Eli Lilly and Company	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
MX2022014786A (es)	2020-05-26	2023-01-16	Truebinding Inc	Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2021257808A2 (en) *	2020-06-17	2021-12-23	Proviva Therapeutics (Hong Kong) Limited	Antibodies to fibroblast activation protein and b7h3
AU2021310926A1 (en)	2020-07-23	2023-03-23	Othair Prothena Limited	Anti-abeta antibodies
PE20231507A1 (es) *	2020-10-02	2023-09-26	Lilly Co Eli	Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
TWI843040B (zh)	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
CN116916957A (zh) *	2021-01-11	2023-10-20	伊莱利利公司	抗N3pGlu淀粉样蛋白β抗体及其用途
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
TW202300518A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
MX2024004514A (es)	2021-10-22	2024-05-07	Lilly Co Eli	Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
MX2024005144A (es)	2021-10-29	2024-05-13	Lilly Co Eli	Compuestos y metodos dirigidos a la interleucina-34.
CA3236560A1 (en)	2021-10-29	2023-05-04	Marcio Chedid	Compounds and methods targeting interleukin-34
IL312380A (en)	2021-10-29	2024-06-01	Lilly Co Eli	Compounds and methods targeting interleukin-34
US20260125460A1 (en)	2021-10-29	2026-05-07	Eli Lilly And Company	Compounds and methods targeting interleukin-34
CA3243602A1 (en)	2022-02-03	2023-08-10	Eli Lilly And Company	Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease
PE20250785A1 (es) *	2022-07-21	2025-03-14	Lilly Co Eli	SOLUCIONES FARMACEUTICAS DE ANTICUERPOS ANTI-N3PGLU Aß Y USOS DE ESTAS
WO2024133925A1 (en)	2022-12-22	2024-06-27	Bioarctic Ab	Antibody which binds to abetape3
IL328051A (en)	2023-11-14	2026-06-01	Lilly Co Eli	Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025228315A1 (en) *	2024-04-28	2025-11-06	Jacobio Pharmaceuticals Co., Ltd.	Anti-n3pglu amyloid beta antibodies and uses thereof
TW202613161A (zh) *	2024-05-16	2026-04-01	大陸商江蘇恆瑞醫藥股份有限公司	抗Ｎ３ｐＧｌｕＡβ抗體及其醫藥用途
WO2025245381A1 (en)	2024-05-23	2025-11-27	The Trustrees Of Dartmouth College	Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025262228A1 (en)	2024-06-20	2025-12-26	Bioarctic Ab	Bispecific binding molecule
WO2026012421A1 (zh) *	2024-07-11	2026-01-15	齐鲁制药有限公司	抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026036133A1 (en) *	2024-08-09	2026-02-12	Scineuro Therapeutics Inc.	POTENT, AGGREGATE-SELECTIVE ANTI-Aβ ANTIBODIES AND USES THEREOF
WO2026055601A1 (en)	2024-09-09	2026-03-12	Eli Lilly And Company	METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES
WO2026122407A1 (en) *	2024-12-04	2026-06-11	Merck Sharp & Dohme Llc	Amyloid beta binder, and uses thereof
WO2026137379A1 (en) *	2024-12-27	2026-07-02	Sironax Switzerland Gmbh	Bispecific antibodies targeting amyloid beta and human cd98hc and methods of uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US7122374B1 (en) *	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (en)	2002-07-24	2004-02-12	Innogenetics N.V.	Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2005018424A2 (en) *	2003-08-18	2005-03-03	Research Foundation For Mental Hygiene, Inc.	Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
CA2538220A1 (en)	2003-09-09	2005-03-24	Takeda Pharmaceutical Company Limited	Use of antibody
JP4851348B2 (ja) *	2004-02-23	2012-01-11	イーライリリーアンドカンパニー	抗Ａβ抗体
AU2005290250A1 (en) *	2004-07-30	2006-04-06	Rinat Neuroscience Corp.	Antibodies directed against amyloid-beta peptide and methods using same
RU2498999C2 (ru)	2006-07-14	2013-11-20	Ац Иммуне Са	Гуманизированное антитело к амилоиду бета
WO2008131298A2 (en) *	2007-04-18	2008-10-30	Elan Pharma International Limited	Prevention and treatment of cerebral amyloid angiopathy
CA2723995A1 (en)	2008-06-12	2009-12-17	Affiris Ag	Compounds for treating symptoms associated with parkinson's disease
WO2010004434A2 (en)	2008-07-09	2010-01-14	University Of Zurich	Method of promoting neurogenesis
KR101706789B1 (ko)	2008-07-21	2017-02-14	프로비오드룩 아게	진단용 항체 검사법
US8795664B2 (en)	2010-06-04	2014-08-05	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	Monoclonal antibodies targeting amyloid beta oligomers
SI3339323T1 (sl) *	2010-08-12	2019-12-31	Eli Lilly And Company	Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe

2011
- 2011-08-09 SI SI201131817T patent/SI3339323T1/sl unknown
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 RS RS20191581A patent/RS59652B1/sr unknown
- 2011-08-09 MA MA35653A patent/MA34461B1/fr unknown
- 2011-08-09 PL PL15196358T patent/PL3042917T3/pl unknown
- 2011-08-09 PT PT181504242T patent/PT3339323T/pt unknown
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/me unknown
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/zh active Active
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 PH PH1/2013/500277A patent/PH12013500277A1/en unknown
- 2011-08-09 RS RS20160129A patent/RS54685B1/sr unknown
- 2011-08-09 EA EA201270813A patent/EA023021B1/ru not_active IP Right Cessation
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/hu unknown
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/me unknown
- 2011-08-09 SI SI201130740T patent/SI2603523T1/sl unknown
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/me unknown
- 2011-08-09 HR HRP20160151TT patent/HRP20160151T1/hr unknown
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/ko active Active
- 2011-08-09 PL PL11745672T patent/PL2603523T3/pl unknown
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/es active Active
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/lt unknown
- 2011-08-09 PL PL18150424T patent/PL3339323T3/pl unknown
- 2011-08-09 RS RS20180323A patent/RS57026B1/sr unknown
- 2011-08-09 PT PT151963584T patent/PT3042917T/pt unknown
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/pt active IP Right Grant
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/zh active Active
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/lt unknown
- 2011-08-09 IL IL285226A patent/IL285226B2/en unknown
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 MX MX2013001716A patent/MX342782B/es active IP Right Grant
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/da active
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/es active IP Right Grant
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/ja active Active
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en not_active Ceased
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/es active Active
- 2011-08-09 ES ES18150424T patent/ES2764728T3/es active Active
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-09-08 UA UAA201301508A patent/UA107600C2/ru unknown
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
2013
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-01-16 CR CR20130016A patent/CR20130016A/es unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/es unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/es unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/es unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/es unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/es unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/es unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
2016
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/ja active Active
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/hr unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/el unknown
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/hr unknown
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/el unknown
2025
- 2025-12-11 NO NO2025056C patent/NO2025056I1/no unknown
- 2025-12-18 FI FIC20250038C patent/FIC20250038I1/fi unknown
- 2025-12-29 FR FR25C1055C patent/FR25C1055I1/fr active Active
2026
- 2026-01-07 NL NL301359C patent/NL301359I2/nl unknown
- 2026-01-20 LT LTPA2026504C patent/LTPA2026504I1/lt unknown

Also Published As

Publication number	Publication date
ME03661B (me)	2020-07-20
GT201300036A (es)	2014-07-16
IL224030B (en)	2022-04-01
LT3339323T (lt)	2020-02-10
CN103068848A (zh)	2013-04-24
PL2603523T3 (pl)	2016-07-29
CA2805114C (en)	2017-12-05
ME03032B (me)	2018-10-20
JP2016179985A (ja)	2016-10-13
JP6395755B2 (ja)	2018-09-26
CO6670526A2 (es)	2013-05-15
NO3042917T3 (es)	2018-07-21
ES2564252T3 (es)	2016-03-21
ME02352B (me)	2016-06-20
ES2764728T3 (es)	2020-06-04
CY1122458T1 (el)	2021-01-27
EP3339323A1 (en)	2018-06-27
MX342782B (es)	2016-10-12
JP5980207B2 (ja)	2016-08-31
SG10201509330XA (en)	2015-12-30
EP2603523B1 (en)	2016-01-27
PL3339323T3 (pl)	2020-05-18
EP3042917A1 (en)	2016-07-13
NZ626665A (en)	2016-04-29
EA201270813A1 (ru)	2013-05-30
US8961972B2 (en)	2015-02-24
HRP20192233T1 (hr)	2020-03-06
IL285226B (en)	2022-10-01
AU2011289629A1 (en)	2013-02-14
HUE037524T2 (hu)	2018-09-28
MX355268B (es)	2018-04-11
MY181969A (en)	2021-01-15
ZA201300437B (en)	2014-06-25
IL285226B2 (en)	2023-02-01
KR101498833B1 (ko)	2015-03-04
SG187586A1 (en)	2013-03-28
DK3042917T3 (en)	2018-04-23
PL3042917T3 (pl)	2018-07-31
DK2603523T3 (en)	2016-03-21
RS59652B1 (sr)	2020-01-31
NO2025056I1 (no)	2025-12-11
DOP2013000029A (es)	2013-03-15
IL285226A (en)	2021-09-30
AU2011289629B2 (en)	2014-07-03
US20140065138A1 (en)	2014-03-06
BR112013004056B1 (pt)	2022-05-17
US20130142806A1 (en)	2013-06-06
FIC20250038I1 (fi)	2025-12-18
UA107600C2 (uk)	2015-01-26
PH12013500277A1 (en)	2017-04-21
MA34461B1 (fr)	2013-08-01
PT3339323T (pt)	2020-01-14
PT3042917T (pt)	2018-05-02
EP3339323B1 (en)	2019-11-13
ES2664128T3 (es)	2018-04-18
HRP20160151T1 (hr)	2016-03-11
CN105111308A (zh)	2015-12-02
MY163521A (en)	2017-09-15
SI3042917T1 (en)	2018-04-30
BR112013004056B8 (pt)	2022-10-18
US8679498B2 (en)	2014-03-25
DK3339323T3 (da)	2020-01-20
SI2603523T1 (sl)	2016-04-29
EA023021B1 (ru)	2016-04-29
WO2012021469A1 (en)	2012-02-16
FR25C1055I1 (fr)	2026-03-06
JP2013536191A (ja)	2013-09-19
RS54685B1 (sr)	2016-08-31
BR112013004056A2 (pt)	2020-08-04
CN103068848B (zh)	2015-11-25
MX2013001716A (es)	2013-10-28
KR20130051989A (ko)	2013-05-21
HK1180703A1 (zh)	2013-10-25
EP3042917B1 (en)	2018-02-21
LTPA2026504I1 (es)	2026-02-10
CA2805114A1 (en)	2012-02-16
CN105111308B (zh)	2019-03-12
CY1120144T1 (el)	2018-12-12
NZ606095A (en)	2014-11-28
PE20130817A1 (es)	2013-07-18
CR20130016A (es)	2013-03-21
EP2603523A1 (en)	2013-06-19
HUE028678T2 (en)	2016-12-28
NL301359I2 (nl)	2026-02-10
RS57026B1 (sr)	2018-05-31
ECSP13012436A (es)	2013-03-28
HRP20180616T1 (hr)	2018-07-13
LT3042917T (lt)	2018-05-10
SI3339323T1 (sl)	2019-12-31

Publication	Publication Date	Title
CL2014000590A1 (es)	2014-10-17	Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
CL2013002888A1 (es)	2014-09-05	Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
CL2012001304A1 (es)	2012-08-03	Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.
MX355268B (es)	2018-04-11	Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
CL2013000843A1 (es)	2014-03-07	Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
CY1122987T1 (el)	2021-10-29	Αντισωματα εναντι αμυλοειδους βητα
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
CL2012002438A1 (es)	2013-09-13	Anticuerpo aislado que se une a peptido ciclico derivado de peptido betaamiloide (ab); inmunoconjugado que comprende dicho anticuerpo; metodo para tratar o prevenir enfermedad de alzheimer que comprende el anticuerpo antes mencionado; kit que comprende el anticuerpo.
CL2008001741A1 (es)	2008-11-21	Anticuerpo quimerico o humanizado o fragmento de los mismos que se unen especificamente a por lo menos un epitope en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados con la formacion de placas amiloides.
CL2008001742A1 (es)	2008-11-21	Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.
CL2014001074A1 (es)	2015-01-09	Anticuerpos monoclonales que es anti proteina de union a adn de tar de 43 kda (tdp-43); polinucleotido que lo codifica; composicion farmaceutica que lo contiene; uso del anticuerpo.
AR074360A1 (es)	2011-01-12	Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
IL206641B (en)	2019-05-30	Recombinant or humanized or isolated antibody or chimeric antibody, or an antibody-binding fragment thereof that selectively binds to a new epitope of humanized amyloid a peptide, a pharmaceutical preparation containing the antibody and its use for the preparation of a pharmaceutical compound for the treatment of amyloidosis
CL2014000400A1 (es)	2014-08-29	Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
BR112013033258A2 (pt)	2017-03-01	moléculas de ligação de anti-alfa sinucleína
CO7250445A2 (es)	2015-04-30	Proteínas de unión a antígeno st2
UY32341A (es)	2010-07-30	Proteínas de unión antígeno novedosas
MX2016005050A (es)	2016-08-17	Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos.
BR112015022123A8 (pt)	2018-05-22	Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
CL2008003197A1 (es)	2010-01-15	Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
CO6602134A2 (es)	2013-01-18	Proteinas de union a antigeno especificas para componente amiloide serico p
CL2013002811A1 (es)	2014-02-28	Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
BR112015012708A2 (pt)	2017-09-12	anticorpos para bmp-6
BRPI1013649A2 (pt)	2019-09-24	anticorpo monoclonal humano que se liga especificamente a vcam-1 e composição para o tratamento de uma doença inflamatória ou câncer compreende o mesmo
AR124605A2 (es)	2023-04-12	Anticuerpos anti-il-36r